Healthcare Financing and Delivery Innovation

News

As US Begins to Tackle High Drug Prices, Congress Gets in the Way

Anna Kaltenboeck writes in Bloomberg Law that Protecting Health Care for All Patients Act legislation would complicate efforts to lower drug prices in the U.S. and undermine Medicare’s new negotiating authority if the bill becomes law.
Read More Read More
News

Drugmaker Data, Price Negotiation Timeline Tee Up Fight With HHS

Anna Kaltenboeck discusses how the Centers for Medicare and Medicaid Services is preparing for prescription drug pricing negotiation with manufacturers with the Inflation Reduction Act now in place.
Read More Read More
News

Preserving Integration For Dual Eligible Individuals After The End Of The Medicare-Medicaid Plan Model

ATI Advisory subject matter experts, Allison Rizer and Nils Franco, share data and insights in this articles as part of as part of this Health Affairs' Forefront series. They detail recent enrollment trends in dual eligible programs, the sunsetting of the Medicare-Medicaid Plan (MMP) model, and the changing role of the Medicare-Medicaid Coordination Office (MMCO). Read the full article for their recommendations for several near term approaches to preserve MMP successes.
Read More Read More
News

More Medicare Advantage Plans Are Offering Extra Supports For Frail Seniors

Forbes recently picked up work created by ATI Advisory to support the assertion of a column on the value of offering beneficiaries supplemental benefits.
Read More Read More
Work

Medicare Advantage Enrollment Trends – February 2023

Analysis of national Medicare Advantage enrollment data between 2022 and 2023 shows that Medicare Advantage gained more than two million enrollees, reaching more than 47% of the Medicare eligible population. Medicare Fee-For-Service enrollment data showed 800,000 fewer enrollees over the same period.
Read More Read More
Podcasts

Untangling Drug Prices

Anna Kaltenboeck joins Yale's Health & Veritas podcast to discuss the drivers of high prices for prescription drugs, and how rebates and negotiation work. Also discussed: pharmaceutical innovation, large vs. small molecules, and the creation of the Inflation Reduction Act.
Read More Read More
1 3 4 5 6 7 17